NEW YORK, Feb. 13 (GenomeWeb News) - The National Cancer Institute last week said it plans to commit about $35.5 million over the next five years to fund projects designed to accelerate the implementation of proteomic analysis technology in monitoring cancer-relevant proteins and peptides in clinical samples.
In its request for applications, the NCI said it is soliciting research applications from investigators "interested in participation in a collaborative network of up to five clinical proteomic technology assessment for cancer teams," which will work to improve "proteomic analysis platforms to reliably identify, quantify, and compare proteins and peptides in complex biological mixtures typical of clinical specimens, including generally obtainable body fluids."
"This initiative is focused on technology improvement and will not support research on fundamental cellular and molecular mechanisms of cancer or on biomarker discovery and validation," the NCI said. "Collectively, the CPTAC teams will function as an interactive network that will be responsible for refining, comparing, and optimizing existing proteomics methods and applications.
"Improvements are sought in areas such as: sample collection and fractionation, and detection, identification, and quantification of proteins or peptides of interest," the NCI said.